News for Healthier Living

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the Recurrent Respiratory Papillomatosis Foundation (RRPF) and authored by 16 leading physicians in the field of recurrent respiratory papillomatosis (RRP) has been published in The Laryngoscope, one of the field's most respected peer-reviewed journals. The paper recommends PAPZIMEOS(tm) (zopapogene imadenovec) as the new standard of care first-line treatment for adults with RRP.

January 20, 2026


January 20 2026

January 19 2026

January 18 2026

January 17 2026

January 16 2026

January 15 2026

January 14 2026

January 13 2026

January 12 2026

January 11 2026

January 10 2026

January 9 2026

January 8 2026

January 7 2026

January 6 2026